Patient factors that predispose individuals to IOI post IV anti-VEGF injections include naturally higher levels of anti-drug antibodies against the anti-VEGF agent, retinal comorbidities such as AMD with a dysfunctional blood-retina barrier, and other pro-inflammatory conditions like uveitis [30]. This evidence concerns the gene VEGFA and age-related macular degeneration.